RT Journal Article
SR Electronic
T1 P81 Audit of HIV testing in a lymphoma clinic
JF Sexually Transmitted Infections
JO Sex Transm Infect
FD BMJ Publishing Group Ltd
SP A42
OP A42
DO 10.1136/sextrans-2015-052126.124
VO 91
IS Suppl 1
A1 Harriet LeVoir
A1 Sarah Wexler
A1 Kate Horn
YR 2015
UL http://sti.bmj.com/content/91/Suppl_1/A42.2.abstract
AB Background/introduction Non-hodgkins lymphoma (NHL) is the second most common malignancy in those with HIV, and AIDS related lymphomas (ARL) have increased as a percentage of first AIDS defining illness (ADI). Hodgkins lymphoma (HL) is a non AIDS defining malignancy but has 10 to 20 times higher incidence in those who are HIV positive. To assist in reducing late diagnosis of HIV, BHIVA guidelines in 2014 highlighted diseases where an HIV test should be offered including NHL and HL. Aim(s)/objectives To establish whether patients newly diagnosed with NHL or HL in a large district general hospital lymphoma clinic were being tested for HIV in accordance with national and local guidelines. Methods Patients newly diagnosed with NHL or HL from January 2013–January 2015 were identified via positive histology results recorded by the laboratory. Identification of HIV testing was via electronic blood results records. View this table:Abstract P81 Table 1 HIV testing in lymphoma Discussion/conclusion Local haematology guidelines from 2014 indicate HIV and HCV/HBV testing for patients prior to Rituximab chemotherapy for lymphoma. The results indicate that since implementing guidelines, more HIV testing occurred, but without an increasing identification of undiagnosed HIV. A 2003 study investigating HIV positivity in newly diagnosed NHL identified HIV positive patients had more aggressive lymphoma histology and increased B symptoms. Continued testing for HIV in lymphoma, especially if presenting with B symptoms, is recommended.